DEA Files Notice of Intent to Schedule 7-Hydroxymitragynine: What It Actually Means — and Who Gets Hurt

NewsAdvocacy

Jul 1

BREAKING ANALYSIS | July 1, 2026 | Kratom Truth Project‍ ‍

By Kratom Truth Project

On July 1, 2026, the Drug Enforcement Administration filed two notices of intent with the Federal Register to temporarily place 7-hydroxymitragynine (7-OH) and several synthetic derivatives into Schedule I of the Controlled Substances Act. The notices publish July 6. A 30-day public comment period on the proposed threshold closes July 31, 2026.

This is not an immediate ban. But without coordinated public response, it becomes one around August 5.

Here is what the notice actually says, what it doesn't say, who it will hurt, and what the 30-day window means for the millions of Americans who depend on 7-OH as a safer alternative to dangerous pharmaceuticals.

What Was Actually Filed

The DEA's notice of intent targets 7-OH above a specified threshold of 0.050% by dry weight. Unlike the FDA's original July 2025 recommendation, which explicitly described its scope as concentrated synthetic products, the DEA's written rule does not exempt natural botanical kratom material.

Also swept in: MP (a chemical rearrangement product of 7-OH), MGM-15, and MGM-16 — synthetic derivatives that do not occur naturally in the plant.

If the DEA issues a final temporary order 30 days after the July 6 publication date (approximately August 5), anyone who manufactures, distributes, or sells 7-OH above the threshold faces the same federal criminal, civil, and administrative penalties as heroin or LSD. The temporary scheduling lasts two years, during which permanent scheduling proceeds through standard rulemaking.

HHS Secretary Robert F. Kennedy, Jr. issued a statement calling 7-OH, MP, MGM-15, and MGM-16 "dangerous opioids that fuel addiction and put American lives at risk." DEA Administrator Terrance Cole described the action as targeting "highly concentrated, synthetic 7-OH products." That characterization conflicts directly with the written rule's lack of any natural product exemption.

That contradiction between Cole's verbal framing and the actual regulatory text is not an accident. It is a gap that the comment period exists to address, and the one the public has until July 31 to challenge.

Buried in the DEA's own justification document is a sentence that undermines the entire regulatory narrative: "consumers of raw plant matrix may experience a modified or attenuated physiological effect due to the competitive, co-occurring alkaloids inherent to M. speciosa." The DEA is acknowledging in its own filing that whole-leaf kratom is pharmacologically distinct from isolated 7-OH. That distinction, which the DEA and AKA are now jointly claiming justifies the scheduling, is nowhere reflected in the actual threshold language of the rule.

The scheduling action comes despite the absence of what researchers consider a clear public health signal. Kirsten Smith, an assistant professor of psychiatry and behavioral sciences at Johns Hopkins University who studies kratom's effects in humans, stated publicly: "We don't really have a public health signal of a lot of adverse events for either kratom or for 7-OH at this time." That assessment from a Johns Hopkins researcher actively studying the substance remains unaddressed in the DEA's filing.

"Opioid" Is the Wrong Word — And It's Being Used Deliberately

Every headline today calls 7-hydroxymitragynine an opioid. HHS Secretary Kennedy called it one. FDA Commissioner Makary called it one. The DEA's notice calls it one. The word is doing enormous political work, and it is scientifically imprecise in ways that matter.

Here is what "opioid" actually means in pharmacology: a substance that binds to opioid receptors in the brain. By that definition, your body produces opioids right now. Endorphins are opioids. The runner's high is caused by opioids. Loperamide — the active ingredient in Imodium, sold next to the candy bars at every pharmacy in America — is an opioid. ‍

The pharmacological framing gets even more specific. Regulators describe 7-OH as a "partial agonist" at mu-opioid receptors, meaning it activates those receptors without fully maxing out their response. Beta-endorphin, the compound your brain releases during intense exercise, grief, laughter, and orgasm, is also a partial agonist at mu-opioid receptors. The "runner's high" is pharmacologically closer to 7-OH than to heroin. This is not a fringe argument. It is the basis on which Johns Hopkins and UCLA researchers have been pursuing 7-OH as a non-respiratory-depressant analgesic. The research doesn't exist yet at clinical trial scale because Schedule I status has made it nearly impossible to conduct. That circularity: ban it before the research exists, then use the absence of research to justify the ban, is a feature of the pharmaceutical regulatory capture playbook, not a bug. ‍

The word the public hears when regulators say "opioid" is heroin, fentanyl, OxyContin: drugs that cause respiratory depression, physical dependence, and mass death. That association is intentional. It is not scientifically accurate when applied to 7-OH. ‍

7-OH binds preferentially to mu-opioid receptors, yes. But receptor binding affinity is not the same as clinical effect. What 7-OH does not do, in peer-reviewed study after peer-reviewed study, is cause the respiratory depression that kills opioid overdose victims. The cause of death in opioid overdoses is not pain relief. It is breathing suppression. Classical opioids suppress respiration at the same receptor sites that produce analgesia. The evidence to date indicates 7-OH does not follow that pattern, which is precisely why researchers at Johns Hopkins and UCLA have been studying it as a potential non-respiratory-depressant pain alternative. ‍

The FDA cited 165 poison control exposure cases involving 7-OH from January through July 2025, in a country of 335 million people, across a market that had expanded dramatically. For comparison, Tylenol sends approximately 50,000 Americans to emergency rooms annually. The DEA's notice cites 9 deaths in the FDA Adverse Event Reporting System and 55 fatal cases in DEA toxicology data since 2019. Not a single confirmed case of death caused by 7-OH in isolation has ever been documented. What the DEA's own filing acknowledges is that the cases it cites almost universally involved polydrug combinations — fentanyl, benzodiazepines, ketamine, and other opioids. The DEA explicitly notes samples "often contained other drug classes, such as opioids (e.g. fentanyl)." FAERS reports are voluntary, unverified, and cannot establish causation — they record only that a substance was present, not that it caused the outcome. Attributing deaths with fentanyl in the toxicology panel to 7-OH is the same methodology we documented in How Science Gets Weaponized — polydrug cases blamed on one substance to manufacture a regulatory narrative. The DEA buried that context in a footnote. The scheduling recommendation is being driven by receptor pharmacology data and political pressure — and a deliberate choice to use language that triggers a specific emotional response in the public and in lawmakers. When you see the word "opioid" applied to 7-OH in coverage of today's DEA action, ask who benefits from that framing. The answer is the same industry that spent two decades telling doctors OxyContin was non-addictive.

The Threshold That Changes Everything

The 0.050% by dry weight threshold, paired with a 1mg per serving limit, is the number that determines exactly which products this action captures and which it leaves alone. Understanding where your products fall against that threshold is the difference between being unaffected and facing a Schedule I ban.

The threshold has three distinct parts. Part A captures raw botanical kratom plant material containing more than 0.050% 7-OH by dry weight. Part B captures synthetic and processed products — extracts, concentrates, edibles, and pressed pills — at either more than 0.050% or more than 1mg of 7-OH per serving, whichever is lower.

The DEA's own press release stated: "This temporary scheduling action does not apply to botanical kratom products that contain naturally occurring 7-OH below the specified threshold." Most natural whole-leaf kratom tests at approximately 0.01–0.02% by dry weight — well below the 0.050% Part A threshold. If you use standard whole-leaf powder or capsules from a GMP-certified vendor, current evidence suggests you are below the threshold and the DEA has indicated this action is not aimed at you.

The concern is concentrated products. Isolated 7-OH products, primarily in tablet form, deliver purified 7-OH well above the 1mg Part B limit and are the clear primary target of this action. Full-spectrum kratom extracts concentrate the plant's complete alkaloid profile, and while their 7-OH content is far lower than isolated products, many still exceed the 1mg per serving limit and could be captured under Part B depending on their concentration. The written rule's dual trigger — 0.050% or 1mg per serving, whichever is lower — means the mg limit becomes the deciding factor for most concentrated products regardless of their overall potency.

The American Kratom Association, which has chosen to publicly support this scheduling action, claims the threshold is designed to protect natural leaf. Their statement reads: "Although 7-OH occurs naturally in trace amounts in the kratom plant, scheduling 7-OH above a certain threshold level does not intend to capture the kratom botanical leaf."

The DEA's press release supports that interpretation for natural leaf below the threshold. But the written rule still contains no explicit natural product exemption, meaning enforcement discretion and written text remain in tension. Until the final order specifies a clear natural product carve-out in writing, extract vendors remain in legal jeopardy regardless of the DEA's stated intent.

The 1mg per article limit is not a minor technical detail. It is the mechanism that determines which concentrated products fall into Schedule I, and it applies regardless of whether a product is an isolated 7-OH tablet or a full-spectrum extract.

AKA's Calculated Betrayal

The American Kratom Association's decision to support this scheduling action is the predictable endpoint of a strategy we have documented on this platform for over a year.

AKA has spent the past 18 months attempting to draw a line between "good kratom" (whole-leaf, which they represent) and "bad kratom" (concentrated 7-OH, which competes with their member vendors' products and creates politically inconvenient headlines). Their July 1 press release made the strategy explicit: "Do not ban kratom because of 7-OH. Ban 7-OH because it is not kratom."

We have covered this argument in depth in our Science vs. Hysteria special report and our 7-OH Science Fraud investigation. The short version: this argument is scientifically wrong, strategically self-defeating, and morally indefensible.

It is scientifically wrong because 7-OH is not a synthetic chemical cooked up in a lab. It is a naturally occurring alkaloid in the Mitragyna speciosa plant, the same plant whose leaf AKA is defending. Concentration does not change the origin of a compound. Morphine is concentrated from poppies. THC is concentrated from cannabis. Caffeine is concentrated from coffee beans. None of them become "synthetic" in the process.

It is strategically self-defeating because it accepts the regulatory premise that potency equals danger, a framework FDA will use to attack progressively less concentrated products until whole-leaf kratom is the only thing left, and then attack that too. This is exactly how the cannabis prohibition playbook worked for fifty years.

It is morally indefensible because the people who depend on concentrated 7-OH products have nowhere else to go. Peer-reviewed survey data from Johns Hopkins Medicine found that 91% of kratom users report taking it to alleviate pain, and 41% specifically to manage opioid withdrawal — a population that skews even more heavily toward chronic pain and opioid dependence when the product in question is a concentrated extract rather than whole leaf. Whole-leaf kratom does not provide adequate relief for every pain condition. AKA knows this. They are making a political calculation at the expense of the most medically vulnerable people in their own community.

Trump Said He Wanted to Approve "Natural 7-OH" — Then His DEA Moved to Ban It

On May 11, 2026, President Donald Trump told reporters in the Oval Office during a maternal health event: "We're looking very seriously at natural 7-OH and getting that approved."

Seven weeks later his own DEA filed a notice of intent to place 7-OH into Schedule I.‍ ‍

That contradiction is not a minor footnote. It is the central political story of today's announcement, and it creates a direct opening for advocates. DEA Administrator Cole's verbal framing that the action targets only "highly concentrated, synthetic" products conflicts with the written rule's actual threshold language. Trump's own stated position that natural 7-OH deserves approval conflicts with his administration's regulatory action. ‍

When a president's public statement and his agency's written rule point in opposite directions within seven weeks, that gap belongs in the administrative record. If you submit a public comment before July 31, citing Trump's May 11 statement directly is not a political argument. It is a factual citation of executive intent that the DEA must address in its response to comments.‍

Who Actually Uses 7-OH — and What Happens to Them

The regulatory narrative describes 7-OH users as reckless consumers buying gummies at gas stations. The reality, documented extensively in user surveys and community data, is substantially different.‍ ‍

The majority of people using concentrated 7-OH products are former prescription opioid patients — people who were on hydrocodone, oxycodone, morphine, or fentanyl for years before their prescriptions were cut off, their insurance changed, or their doctors retired. Whole-leaf kratom helped but wasn't sufficient for their pain levels. Concentrated 7-OH gave them functional pain relief without respiratory depression, cognitive impairment, or $500-a-month pharmacy bills.‍ ‍

These are not drug seekers. They are chronic pain patients who the American healthcare system failed, found a solution that works, and will now be forced back to the system that failed them, or to the street drug market that will kill them.‍ ‍

Schedule I classification eliminates research pathways. Once 7-OH is in Schedule I, conducting clinical studies to establish its actual safety and efficacy profile becomes nearly impossible. This is not a side effect of the policy. It is the feature. As we documented in Following the Money, the pharmaceutical industry's interest in kratom prohibition is directly tied to eliminating competition for the opioid treatment market, valued at over $27 billion annually. Schedule I status kills the research that would establish a natural product as a legitimate alternative.‍ ‍

What happens to the patient who was managing severe degenerative disc disease on $45/month worth of 7-OH extract?‍ ‍

They either return to oxycodone, if they can find a doctor willing to prescribe it and insurance that will cover it. They switch to Suboxone, if they can access an approved prescriber and tolerate four months of brutal withdrawal when they eventually want to stop. Or they go to the street, where fentanyl contamination kills 80,000 Americans a year.‍ ‍

Prohibition is not neutral. Prohibition has a body count.

ACTION REQUIRED

Submit Your Public Comment Before July 31

HHS Docket HHS-OASH-2026-0232 opens July 6. KTP built a free generator that writes your personalized comment in under 2 minutes — no form letter, no account required.

Generate Your Comment → Docket opens July 6 · Closes July 31

The 7-OH fight is moving fast and the mainstream press is getting it wrong. Subscribe to KTP updates →

The Real Problem Was Never 7-OH

The actual public health concern driving the "gas station heroin" narrative is largely a contamination story, not a 7-OH story.

Significant numbers of products marketed as "kratom extract" or "7-OH" in gas stations and smoke shops have been found to contain tianeptine, a European antidepressant with severe opioid-like withdrawal that creates intense physical dependence far more brutal than pure 7-OH. The withdrawal from tianeptine-contaminated products lasts two to four weeks and is described by users as worse than pharmaceutical opioid withdrawal.

When those users experience that withdrawal and report it to doctors, media, or FDA databases, it gets logged as "kratom addiction" or "7-OH dependence." FDA and DEA then cite those cases as evidence that 7-OH is dangerous. The loop closes: a contamination problem creates the regulatory justification for banning the product that didn't cause the harm.

We documented this in detail in our 7-OH Science Fraud special report. The solution to tianeptine contamination is mandatory third-party lab testing with adulterant screening, the same testing GMP-certified kratom vendors already do. Schedule I classification makes lab testing impossible and drives production entirely underground.

The 7-HOPE Alliance Is Mobilizing — Here's the Timeline

Unlike AKA, the 7-HOPE Alliance (7-Hydroxy Outreach for Public Education) is opposing this scheduling action. Their July 1 statement clarifies what the notice of intent does and doesn't mean: "7-OH has not been immediately banned or scheduled. What was announced on July 1st is a federal request for public comment on a proposed threshold."

7-HOPE is convening a national advocate call on July 7 at 7pm ET where they will announce their action plan. Registration is available at 7hopealliance.org/federal. They are explicitly asking advocates to hold on contacting lawmakers until after that call, when a coordinated response strategy will be released.

The most critical action window is the HHS public comment period, which closes July 31, 2026.

This is where the fight actually happens. The 2016 DEA attempt to schedule both mitragynine and 7-OH was withdrawn after an unprecedented public response: over 140,000 comments, bipartisan congressional opposition, and patient testimony that forced the agency to acknowledge the human cost of prohibition. That response worked because it was organized, factual, and driven by real patients with real stories. The DEA's 2016 withdrawal created a formal administrative record acknowledging the public interest in kratom access, a record today's notice does not address or distinguish. That omission belongs in your comment.

The comment period is not a formality. It is on the record. It is part of the administrative record that any subsequent legal challenge or any future administration's reconsideration will be built on. It is also, under 21 U.S.C. 811(h)(6), one of the only available avenues: the DEA's notice explicitly states that temporary scheduling orders are not subject to judicial review. The comment period is not a procedural nicety. It is the mechanism.

What to Do Right Now

1. Attend the 7-HOPE advocate call — July 7, 7pm ET Register at 7hopealliance.org/federal. This is where the coordinated response strategy will be announced.

2. Submit a public comment before July 31 The HHS comment docket will be live at regulations.gov. Your comment should be personal, factual, and specific — not a form letter. Describe your medical situation, why you use 7-OH or kratom extracts, what alternatives are available to you, and what would happen to your quality of life if access were eliminated. First-person accounts from actual patients carry significant weight. Use our comment generator here.

3. Sign up for 7-HOPE text alerts Text your state name to 818-287-6644 to receive real-time updates on the federal action.

4. Share this analysis The mainstream coverage of today's announcement ranges from inaccurate to actively misleading. People who depend on 7-OH need accurate information about what was actually filed, what the timeline is, and what the comment window means. Share this piece with anyone in the kratom community.

The Bigger Picture

What happened today follows a playbook we have documented extensively at the Kratom Truth Project. FDA recommendation. Congressional pressure letters. Media campaign characterizing a natural botanical as a "synthetic opioid." DEA scheduling action. The sequence is not spontaneous. It reflects coordinated effort by interests whose revenues depend on eliminating plant-based alternatives to pharmaceutical pain management.

We are not arguing that all 7-OH products are safe or that the market had no problems. The gas-station gummy market was largely unregulated and contamination, particularly tianeptine, was a genuine public health issue. Regulation, testing requirements, and adult-only retail restrictions would have addressed those problems.

What is being pursued instead is prohibition, which does not solve contamination, does not protect consumers, and does not help a single chronic pain patient find safer care. It eliminates a harm reduction option for the most vulnerable population in the opioid crisis, protects pharmaceutical market share, and ensures that the research needed to definitively establish 7-OH's safety profile can never be conducted.

The pharmaceutical conflict of interest embedded in today's action deserves explicit naming. Not as speculation, but as documented financial reality. Indivior PLC, manufacturer of SUBLOCADE (injectable buprenorphine) and Suboxone, generates over $240 million per quarter in US revenue from opioid use disorder treatments. Their own SEC filings tell investors to expect continued growth due to "regulatory and legislative actions" expanding the OUD treatment market, and state explicitly that the company "supports these actions." OpenSecrets lists Indivior among significant lobbying spenders in the US pharmaceuticals and health products industry. 7-OH is an over-the-counter alternative that chronic pain patients access for $45 a month without a prescription, without a DEA-licensed prescriber, and without the four-month withdrawal Suboxone requires when patients want to stop. That is not a coincidence of market positioning. It is a direct competitive threat to a $27 billion annual industry.

We are not asserting that Indivior funded today's scheduling action. We are asserting that the companies who benefit most from it are the same companies that lobby most aggressively on the regulatory framework governing opioid treatment, and that the public deserves to know that context when evaluating who is driving the "protect public health" narrative. The lobbying disclosure records are public. The financial interests are documented in SEC filings. The connections are there to investigate. KTP will follow them.

Schedule I status doesn't just ban a substance. It bans the science. Every peer-reviewed study suggesting 7-OH's harm reduction potential was conducted under the narrow DEA research license framework. Once 7-OH is in Schedule I, that research pipeline closes. The FDA will then cite the absence of clinical trial data as justification for permanent scheduling. The agency creates the conditions that produce the evidence it needs to maintain the ban. This is not a theory. It is the documented regulatory history of cannabis, which spent 50 years in Schedule I while the federal government simultaneously held a patent on cannabinoids as neuroprotectants. The research that would prove 7-OH is safer than Suboxone can never be conducted if 7-OH is in Schedule I. That outcome benefits exactly one industry.

The comment period closes July 31. If you have a story, the administrative record needs to hear it.

Related KTP Coverage:

The Kratom Truth Project is an independent investigative journalism platform with no corporate funding or pharmaceutical industry affiliations. All claims are sourced from publicly available government documents, peer-reviewed research, and regulatory filings.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making decisions about your health or treatment.If 7-OH Is "Synthetic," Where's the Patent? The Contradiction at the Heart of the Ban